Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer.
Cao JQ, Surgeoner B, Manna M, Boileau JF, Gelmon KA, Brackstone M, Brezden-Masley C, Jerzak KJ, Prakash I, Sehdev S, Wong SM, Bouganim N, Cescon DW, Chia S, Dayes IS, Joy AA, Henning JW. Cao JQ, et al. Among authors: dayes is. Curr Oncol. 2024 Nov 15;31(11):7226-7243. doi: 10.3390/curroncol31110533. Curr Oncol. 2024. PMID: 39590163 Free PMC article.
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.
Manna M, Gelmon KA, Boileau JF, Brezden-Masley C, Cao JQ, Jerzak KJ, Prakash I, Sehdev S, Simmons C, Bouganim N, Brackstone M, Cescon DW, Chia S, Dayes IS, Edwards S, Hilton J, Joy AA, Laing K, Webster M, Henning JW. Manna M, et al. Among authors: dayes is. Curr Oncol. 2024 Oct 24;31(11):6536-6567. doi: 10.3390/curroncol31110484. Curr Oncol. 2024. PMID: 39590115 Free PMC article.
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Williamson E, Pugh J, Manning G, Brown S, Burnett S, Hall E. van As N, et al. Among authors: dayes i. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi: 10.1056/NEJMoa2403365. N Engl J Med. 2024. PMID: 39413377 Free PMC article. Clinical Trial.
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Spratt DE, et al. Among authors: dayes is. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1461. doi: 10.1016/j.ijrobp.2024.08.044. Epub 2024 Sep 23. Int J Radiat Oncol Biol Phys. 2024. PMID: 39320298 Free article. No abstract available.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free PMC article. Clinical Trial.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM. Lee WR, et al. Among authors: dayes is. J Clin Oncol. 2024 Jul 10;42(20):2377-2381. doi: 10.1200/JCO.23.02445. Epub 2024 May 17. J Clin Oncol. 2024. PMID: 38759121 Free PMC article. Clinical Trial.
Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma.
Schep DG, Vansantvoort J, Dayes I, Lukka H, Quan K, Kapoor A, Chow T, Chu W, Swaminath A. Schep DG, et al. Among authors: dayes i. Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):832-837. doi: 10.1016/j.ijrobp.2023.12.005. Epub 2023 Dec 12. Int J Radiat Oncol Biol Phys. 2024. PMID: 38092258
59 results